New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
10:03 EDTDUK, GMCR, CVE, FTI, SYMC, VPHM, RPM, RAS, PDH, MLNX, MXIM, CS, CLF, CELG, BSXOn The Fly: Analyst Upgrade Summar
Today's noteworthy upgrades include: Boston Scientific (BSX) upgraded to Outperform from Neutral at Credit Suisse... Celgene (CELG) upgraded to Buy from Neutral at BofA/Merrill... Cliffs Natural (CLF) upgraded to Buy from Hold at Deutsche Bank... Credit Suisse (CS) upgraded to Outperform from Neutral at Exane BNP Paribas... Maxim Integrated (MXIM) upgraded to Outperform from Perform at Oppenheimer... Mellanox (MLNX) upgraded to Buy from Neutral at UBS... PetroLogistics (PDH) upgraded to Buy from Neutral at Citigroup... RAIT Financial (RAS) upgraded to Outperform from Market Perform at FBR Capital... RPM (RPM) upgraded to Perform from Underperform at Oppenheimer... ViroPharma (VPHM) upgraded to Buy from Neutral at BofA/Merrill... Symantec (SYMC) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Overweight from Equal Weight at Morgan Stanley... Cenovus Energy (CVE) upgraded to Overweight from Neutral at JPMorgan... Green Mountain (GMCR) upgraded to Buy from Hold at Argus... Duke Energy (DUK) upgraded to Buy from Neutral at UBS.
News For BSX;CELG;CLF;CS;MXIM;MLNX;PDH;RAS;RPM;VPHM;SYMC;FTI;CVE;GMCR;DUK From The Last 14 Days
Check below for free stories on BSX;CELG;CLF;CS;MXIM;MLNX;PDH;RAS;RPM;VPHM;SYMC;FTI;CVE;GMCR;DUK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 14, 2014
09:02 EDTBSXBoston Scientific receives CE mark for Ranger drug-coated balloon
Boston Scientific has received CE Mark for the Ranger Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Balloon provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.
08:15 EDTCLFCliffs Natural recommends voting WHITE proxy card
Subscribe for More Information
July 10, 2014
15:40 EDTSYMCSymantec calls active on renewed interest from private equity
Subscribe for More Information
15:26 EDTSYMCSymantec is seeing renewed interest from private equity, says dealReporter
Subscribe for More Information
12:23 EDTCLFCasblanca Capital condemns Cliffs Natural's compensation practices in letter
Casablanca Capital LP, the beneficial owner of approximately 5.2% of Cliffs Natural Resources, issued a letter to shareholders in connection with Casablanca’s campaign for fundamental change at Cliffs and its nomination of six director candidates for election to the Board of Directors at the company’s upcoming 2014 Annual Meeting of Shareholders on July 29. In the letter, Casablanca details escalating management compensation while shareholder returns have plummeted, the opaque nature of the management bonus and review process, and the ways in which bonus compensation metrics have changed from year to year in an apparent effort by the Cliffs Board to justify management bonuses despite severe underperformance. Casablanca reiterates that, in contrast to the current 0.3% of Cliffs shares that the current Board and management team owns, Casablanca has economically aligned itself with the interests of fellow shareholders, with Casablanca owning 5.2% of Cliffs shares and with Lourenco Goncalves’ personal investment of $1.5M in Cliffs’ shares. Donald Drapkin, Chairman of Casablanca said, “The Cliffs Board and management team have been pursuing their own personal agendas and enrichment at the expense of shareholders for far too long. It is time for the gravy train to end and for the Board to be held accountable. We are confident that on July 29 Cliffs’ shareholders will vote to support a slate of new directors who will reverse the outrageous value destruction and stop the pattern of excessive compensation and self-dealing at Cliffs.”
08:35 EDTCLFBofA/Merrill steel analysts hold an analyst/industry conference call
Global Steel Analysts review market conditions in Asia, Europe and the U.S. and discuss recent price moves in iron ore, met coal and global steel on an Analyst/Industry conference call. Covered companies AKS, ATI, CLF, CMC, GGB, MTL, NUE, RS, SCHN, SID, STLD, TX and X may be discussed on the Analyst/Industry conference call to be held on July 14 at 10 am.
07:08 EDTCSECB keeps tight grip on banks with health check results, Reuters says
The European Central Bank is targeting to keep a tight grip banks in the final phase of a balance sheet health check in October, giving them only 48 hours to review the test results before publishing them, according to Reuters, citing two people familiar with the matter. The assessment will look into banks’ balance sheets and measure their ability to handle shock and stress. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS).
06:45 EDTCSCredit Suisse asks sentencing for aiding tax evasion be delayed, WSJ reports
Subscribe for More Information
July 9, 2014
16:25 EDTCELGCelgene reports 11.9% passive stake in GlobeImmune
Subscribe for More Information
11:57 EDTCELGCelgene shares higher despite missing primary endpoint in Otezla trial
Subscribe for More Information
09:35 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AA FB AMZN TSLA TWTR MU NFLX GG CELG
09:13 EDTCELGOn The Fly: Pre-market Movers
Subscribe for More Information
07:05 EDTGMCRKeurig now exclusive manufacture of Harris Teeter K-Cup packs
Subscribe for More Information
07:04 EDTCELGCelgene says OTEZLA did not achieve primary endpoint in Phase III trial
Celgene Corporation announced results of its phase III POSTURE study evaluating OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4, in patients with active ankylosing spondylitis. The OTEZLA arms did not achieve statistically significant improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS 20 response at week 16. However, in a prespecified analysis, meaningful efficacy was observed at Week 24 in a large subset of patients with early-stage disease. Evaluation of the efficacy results is ongoing. An independent data monitoring committee recommended that the study proceed unchanged, based on an assessment of the safety and efficacy data at week 24. According to the protocol, magnetic resonance imaging data will be collected in a subgroup of subjects at week 52 and at additional time points, and radiographs will be taken on all study patients at week 104 and at additional time points. The safety and tolerability data observed in the POSTURE study are consistent with previously reported phase II data in ankylosing spondylitis, as well as six phase III studies of OTEZLA in psoriatic arthritis or psoriasis. No new safety signals were observed. The evaluation of safety and efficacy in the treatment arms is ongoing and the results of the study will be presented at an upcoming medical meeting. These results are from an investigational phase III study. OTEZLA is not approved for the treatment of patients with ankylosing spondylitis in any country.
July 8, 2014
10:28 EDTBSXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A.O. Smith (AOS) initiated with an Outperform at Northland... Abengoa Yield (ABY) initiated with a Buy at BofA/Merrill... Aflac (AFL) initiated with a Buy at Drexel Hamilton... Aspen Aerogels (ASPN) initiated with a Buy at Canaccord... Boston Scientific (BSX) initiated with a Buy at CRT Capital... CSC (CSC) initiated with an Underweight at Morgan Stanley... Consumer Portfolio (CPSS) initiated with a Buy at Compass Point... Credit Acceptance (CACC) initiated with a Sell at Compass Point... Intuitive Surgical (ISRG) initiated with a Neutral at BTIG... Masimo (MASI) initiated with a Buy at BTIG... Memorial Resource (MRD) initiated with an Overweight at Barclays... MetLife (MET) initiated with a Buy at Drexel Hamilton... Mueller Water (MWA) initiated with a Market Perform at Northland... New York REIT (NYRT) initiated with a Market Perform at JMP Securities... NorthStar Asset Management (NSAM) initiated with a Market Perform at Keefe Bruyette... Ophthotech (OPHT) initiated with an Outperform at Oppenheimer... Performance Sports Group (PSG) initiated with an Outperform at Wedbush... Prudential (PRU) initiated with a Buy at Drexel Hamilton... RCS Capital (RCAP) initiated with a Neutral at BofA/Merrill... Santander Consumer (SC) initiated with a Neutral at Compass Point... Silicon Laboratories (SLAB) initiated with a Buy at MKM Partners... St. Jude Medical (STJ) initiated with a Buy at CRT Capital... Starwood Waypoint (SWAY) initiated with an Outperform at Keefe Bruyette... T-Mobile (TMUS) initiated with an Outperform at BMO Capital... TherapeuticsMD (TXMD) initiated with an Outperform at FBR Capital... Waddell & Reed (WDR) initiated with an Outperform at William Blair... Xerox (XRX) initiated with an Overweight at Morgan Stanley.
07:49 EDTCSEU banks on pace to shed record EUR100B on unwanted loans, FT says
Subscribe for More Information
07:33 EDTPDHPetroLogistics announces expiration of waiting period for acquisition
Subscribe for More Information
07:32 EDTCSSemiconductor Equipment & Materials International to hold a conference
SEMICON West to be held in San Francisco on July 8-10.
06:36 EDTBSXBoston Scientific initiated with a Buy at CRT Capital
Subscribe for More Information
05:55 EDTGMCRStocks with implied volatility movement; TSLA GMCR
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use